NEWSLETTER
Biased DNA Crime Scenes
Cell Crunch (Issue 2021.01.29)
Reach out on Twitter with feedback and questions. Receive this free newsletter every Friday morning by clicking here.
I’ve spent more time than many will believe [making microscopic observations], but I’ve done them with joy, and I’ve taken no notice those who have said why take so much trouble and what good is it? — Antonie van Leeuwenhoek
📰 Bioengineering in the News
Now 100% more streamlined.
BIASED GENETIC GENEALOGIES: An investigation by The Atlantic found that, out of more than 100 homicide cases solved using genetic genealogy — which helped identify the Golden State Killer — only four involved a Black victim. The Atlantic. Link
THE FUTURE IS BACON: A last-minute deal by the Trump administration may speed up the approval of gene-edited animals. Future Human. Link
AND MORE BACON: Atlast Food Co., based in Albany, New York, is using mycelium to create faux pork. Forbes. Link
DELETED DNA DATA REAPPEARS: ‘A technical snafu’ on the popular DNA database site, GEDmatch, caused data that had been deleted to reappear for about two days. Future Human. Link
RECYCLED FASHION: Companies like Bolt Threads, Evrnu and Werewool featured in article on recycling technologies for clothes. The New York Times. Link
GOVERNMENT vs. BIOTHREATS: The Commission on Biodefense released recommendations for detecting and stopping pandemics, both natural and man-made. Axios. Link
TALEN vs. CRISPR: TALENs are up to five times better than CRISPR-Cas9 when it comes to editing DNA inside of densely-packed heterochromatin, according to a study from researchers at the University of Illinois. Press Release. Link
FOOD ALLERGIES: Ukko, an Israeli food biotech company, recently raised $40M in a Series B round. The company is developing food proteins that avoid triggering allergic reactions. Forbes. Link
LOOK TO THE FUTURE: Ronit Langer, a Scoville Fellow at the Carnegie Endowment for International Peace, imagines how young people will alter the future of biotechnology. Bioeconomy.XYZ. Link
CHEAPER GENE THERAPIES: Cell and gene therapies are currently expensive, but new technology could bring down costs. Labiotech.eu. Link
SINGLE CELLS: Take an in-depth look at single-cell sequencing technologies in this explainer article. Labiotech.eu. Link
💳Industry Updates
Synthetic biology companies raised about $7.8 billion in 2020, according to a market report. SynBioBeta. Link
Solugen, a Houston, Tx. based developer of biomanufactured chemicals, skipped out on a round of funding, last year, that would have valued the company at more than $1 billion. That’s according to a report from Tech Crunch. Link
Arcadia Biosciences, based in Davis, Ca., announced a $25.1 million private stock placement. The company develops crops and food ingredients with enhanced nutritional properties. Press Release. Link
Verve Therapeutics, based in Cambridge, Ma., raised $94M in a Series B round of financing. The company develops gene-editing medicines for cardiovascular disease. Press Release. Link
Mammoth Biosciences, the San Francisco, Ca. based CRISPR company, announced a partnership with Agilent Technologies to develop a CRISPR-based diagnostic test for COVID-19. Fierce Biotech. Link
Droplet Genomics, Lithuanian biotech startup, raised €1 million to commercialize their droplet-based microfluidics platform. The funding was led by Practica Capital. SynBioBeta. Link
Until Monday,
— Niko
Thanks for reading Cell Crunch, part of Bioeconomy.XYZ. If you enjoy this newsletter, please share it with a friend or colleague. Reach me with tips and feedback @NikoMcCarty or via email.
